ImmunityBio | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 32.06 M

LB filings
2025.11.05 11:08
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 32.06 M, beating the estimate of USD 31.88 M.

EPS: As of FY2025 Q3, the actual value is USD -0.07, beating the estimate of USD -0.108.

EBIT: As of FY2025 Q3, the actual value is USD -30.11 M.

Segment Revenue

  • Total Revenue and Other Income: $33.7 million in Q3 2025, up from $26.4 million in Q2 2025.
  • Product Revenue: $31.8 million in Q3 2025, a 434% increase from $6.0 million in Q3 2024.

Operational Metrics

  • Net Loss: $67.3 million in Q3 2025, compared to $85.7 million in Q3 2024, showing a reduction in loss.
  • Research and Development Expense: Increased by $0.8 million to $51.2 million in Q3 2025 from $50.4 million in Q3 2024.
  • Selling, General and Administrative Expense: Increased by $0.4 million to $36.3 million in Q3 2025 from $35.9 million in Q3 2024.

Cash Flow

  • Cash Position: $257.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025, up from $153.7 million as of June 30, 2025.
  • Net Cash Used in Operating Activities: - $68.9 million in Q3 2025, compared to - $98.8 million in Q3 2024.

Unique Metrics

  • ANKTIVA Unit Growth: 467% unit sales volume growth year-to-date 2025 compared to fiscal year 2024.

Outlook / Guidance

ImmunityBio anticipates continued strong demand for ANKTIVA, with plans to expand its reach to a broader population of bladder cancer patients. The company is optimistic about the potential growth opportunities for its science and its ability to address unmet needs in cancer treatment.

Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.